TAXOL® ( paclitaxel ) for Adjuvant Treatment of Node Positive Breast Cancer. Oncologic Drugs Advisory Committee September 17, 1999. TAXOL® ( paclitaxel ) for Adjuvant Treatment of Node Positive Breast Cancer Oncologic Drug Advisory Committee INTRODUCTION. David Tuck, M.D.
Oncologic Drugs Advisory Committee
September 17, 1999
David Tuck, M.D.
Bristol-Myers Squibb Company
Pharmaceutical Research Institute
M.D. Anderson Cancer Center - Houston, Texas
Director CALGB Statistical Center
Duke University - Durham, North Carolina
University of California at San Francisco, California
Memorial Sloan-Kettering Cancer Center - New York, New York
North Central Cancer Treatment Group (NCCTG)
Southwest Oncology Group (SWOG)
TAXOL® (paclitaxel) administered sequential to standard combination chemotherapy is indicated for the adjuvant treatment of node positive breast cancer